Chronic cutaneous lupus erythematosus

Chronic cutaneous lupus erythematosus (CCLE) is a form of lupus that primarily affects the skin without necessarily involving internal organs. It is the most common subtype of cutaneous lupus erythematosus and encompasses several clinical variants, the most well-known being discoid lupus erythematosus (DLE). Other variants include lupus erythematosus profundus (lupus panniculitis), chilblain lupus erythematosus, and lupus erythematosus tumidus. CCLE is an autoimmune condition in which the immune system mistakenly attacks healthy skin tissue, leading to chronic inflammatory skin lesions. The hallmark features of CCLE, particularly in its discoid form, include well-defined, coin-shaped (discoid) erythematous plaques with adherent scaling, follicular plugging, and skin atrophy. These lesions most commonly appear on sun-exposed areas such as the face, scalp, and ears. Over time, lesions can cause permanent scarring, dyspigmentation (both hypopigmentation and hyperpigmentation), and scarring alopecia (permanent hair loss) when the scalp is involved. The condition tends to be photosensitive, meaning ultraviolet light exposure can trigger or worsen flares. While CCLE is generally confined to the skin, approximately 5-25% of patients with DLE may progress to systemic lupus erythematosus (SLE), which can affect multiple organ systems including the kidneys, joints, and blood. Treatment of CCLE focuses on preventing new lesions, controlling existing inflammation, and minimizing scarring. First-line management includes rigorous sun protection (broad-spectrum sunscreen, protective clothing) and topical therapies such as potent topical corticosteroids and topical calcineurin inhibitors. For more widespread or refractory disease, antimalarial medications, particularly hydroxychloroquine, are considered the systemic treatment of choice. In resistant cases, additional immunosuppressive agents such as methotrexate, mycophenolate mofetil, or dapsone may be used. Early diagnosis and treatment are important to prevent irreversible scarring and disfigurement.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Chronic cutaneous lupus erythematosus